
WHAT IS CLAIMED IS:

1. A method of treating transthyretin (TTR) amyloidosis in a subject in need thereof, the method comprising administering to a subject in need thereof a therapeutically effective amount of Compound 1, having the formula:



or a pharmaceutically acceptable salt thereof, wherein said therapeutically effective amount is a total daily dosage of about 10 mg to 2,000 mg.

2. The method of claim **1**, wherein said therapeutically effective amount is a total daily dosage of about 10 mg to 50 mg.

3. The method of claim **1**, wherein said therapeutically effective amount is a total daily dosage of about 50 mg to 300 mg.

4. The method of claim **1**, wherein said therapeutically effective amount is a total daily dosage of about 50 mg to 150 mg.

5. The method of claim **1**, wherein said therapeutically effective amount is a total daily dosage of about 150 mg to 800 mg.

6. The method of claim **1**, wherein said therapeutically effective amount is a total daily dosage of about 800 mg to 1,600.

7. The method of claim **1**, wherein said therapeutically effective amount is a total daily dosage of about 800 mg.

8. The method of claim **1**, wherein said therapeutically effective amount is a total daily dosage of about 1,600 mg.

9. The method of any one of claims **1** to **8**, wherein Compound 1 is in HCl salt form.

10. The method of any one of claims **1** to **9**, wherein said Compound 1 is administered orally.


11. The method of any one of claims **1** to **10**, wherein said Compound 1 is administered once daily.

12. The method of any one of claims **1** to **10**, wherein said Compound 1 is administered twice daily.

13. The method of any one of claims **1** to **10**, wherein said Compound 1 is administered three times daily.

14. The method of any one of claims **1** to **10**, wherein said Compound 1 is administered four times daily.

15. A method of treating transthyretin (TTR) amyloidosis in a subject in need thereof, the method comprising administering to a subject in need thereof a therapeutically effective amount of Compound 1, having the formula:



or a pharmaceutically acceptable salt thereof, wherein the therapeutically effective amount of Compound 1 maintains a trough blood plasma concentration of Compound 1 of at least 5 μM.

16. The method of claim **15**, wherein the therapeutically effective amount of Compound 1 maintains a trough blood plasma concentration of Compound 1 of at least 6 μM.

17. The method of claim **15**, wherein the therapeutically effective amount of Compound 1 maintains a trough blood plasma concentration of Compound 1 of at least 7.5 μM.

18. The method of claim **15**, wherein the therapeutically effective amount of Compound 1 maintains a trough blood plasma concentration of Compound 1 of at least 8 μM.

19. The method of claim **15**, wherein the therapeutically effective amount of Compound 1 maintains a trough blood plasma concentration of Compound 1 from 5 to 30 μM.

20. The method of claim **15**, wherein the therapeutically effective amount of Compound 1 maintains a trough blood plasma concentration of Compound 1 from 5 to 25 μM.

21. The method of claim **15**, wherein the therapeutically effective amount of Compound 1 maintains a trough blood plasma concentration of Compound 1 from 6 to 20 μM.

22. The method of claim **15**, wherein the therapeutically effective amount of Compound 1 maintains a trough blood plasma concentration of Compound 1 from 7.5 to 15 μM.

23. The method of claim **15**, wherein the therapeutically effective amount of Compound 1 maintains a trough blood plasma concentration of Compound 1 from 7.5 to 10 μM.

24. The method of any one of claims **1** to **23**, wherein said TTR amyloidosis is a disease or condition selected from the group consisting of familial amyloid polyneuropathy, familial amyloid cardiomyopathy, senile systemic amyloidosis, central amyloidosis, ocular amyloidosis, Leptomeningeal amyloidosis, oculoleptomeningeal amyloidosis, vitreous amyloidosis, gastrointestinal amyloidosis, neuropathic amyloidosis, non-neuropathic amyloidosis, non-hereditary amyloidosis, reactive/secondary amyloidosis, cerebral amyloidosis.

25. The method of claim **24**, wherein said TTR amyloidosis is Leptomeningeal amyloidosis.

26. The method of claim **25**, wherein said Leptomeningeal amyloidosis is characterized by a TTR protein that comprises an aspartic acid to glycine mutation at position 18 (D18G).

27. The method of claim **25**, wherein said Leptomeningeal amyloidosis is characterized by a TTR protein that comprises a glycine to arginine mutation at position 53 (G53R).

28. The method of claim **25**, wherein said Leptomeningeal amyloidosis is characterized by a TTR protein that comprises a tyrosine to cysteine mutation at position 114 (Y114C).

29. The method of claim **25**, wherein said Leptomeningeal amyloidosis is characterized by a TTR protein that comprises a threonine to proline mutation at position 49 (T49P).

30. The method of any one of claims **1** to **23**, wherein said TTR amyloidosis is transthyretin amyloidosis (ATTR) cardiomyopathy or transthyretin amyloidosis (ATTR) polyneuropathy.

31. The method of claim **30**, wherein said TTR amyloidosis is characterized by a TTR protein that comprises a threonine to alanine mutation at position 60 (T60A).

32. The method of claim **30**, wherein said TTR amyloidosis is characterized by a TTR protein that comprises a proline to serine mutation at position 24 (P24S).

33. The method of claim **30**, wherein said TTR amyloidosis is characterized by a TTR protein that comprises an aspartic acid to alanine mutation at position 38 (D38A).

34. The method of claim **30**, wherein said TTR amyloidosis is characterized by a TTR protein that comprises a leucine to histidine mutation at position 58 (L58H).

35. The method of any one of claims **1** to **23**, wherein said TTR amyloidosis is transthyretin amyloidosis (ATTR) cardiomyopathy.

36. The method of claim **35**, wherein said ATTR cardiomyopathy is wild-type ATTR cardiomyopathy (ATTRwt-CM).

37. The method of claim **35**, wherein said ATTR cardiomyopathy is familial ATTR cardiomyopathy (ATTRm-CM).

38. The method of claim **37**, wherein said ATTRm-CM is characterized by a TTR protein that comprises a valine to isoleucine mutation at position 122 (V122I).

39. The method of claim **37**, wherein said ATTRm-CM is characterized by a TTR protein that comprises a threonine to proline mutation at position 49 (T49P).

40. The method of any one of claims **1** to **23**, wherein said TTR amyloidosis is transthyretin amyloidosis (ATTR) polyneuropathy.

41. The method of claim **40**, wherein said ATTR polyneuropathy is wild-type ATTR polyneuropathy (ATTRwt-PN).

42. The method of claim **40**, wherein said ATTR polyneuropathy is familial ATTR polyneuropathy (ATTRm-PN).

43. The method of claim **42**, wherein said ATTRm-PN is characterized by a TTR protein that comprises a valine to methionine mutation at position 30 (V30M).

44. The method of claim **42**, wherein said ATTRm-PN is characterized by a TTR protein that comprises a phenylalanine to leucine mutation at position 64 (F64L).

45. The method of claim **42**, wherein said ATTRm-PN is characterized by a TTR protein that comprises a tyrosine to cysteine mutation at position 114 (Y114C).

46. The method of any one of claims **35** to **39**, wherein administration of a therapeutically effective amount of Compound 1 in a subject with ATTR cardiomyopathy improves, stabilizes or delays worsening in New York Heart Association (NYHA) functional classification of subjects.

47. The method of claim **46**, wherein administration of a therapeutically effective amount of Compound 1 reduces the New York Heart Association (NYHA) functional classification of the subject.

48. The method of claim **47**, wherein the NYHA functional classification is reduced from class IV to class III, from class IV to class II, or from class IV to class I.

49. The method of claim **47**, wherein the NYHA functional classification is reduced from class III to class II.

50. The method of claim **47**, wherein the NYHA functional classification is reduced from class III to class I.

51. The method of claim **47**, wherein the NYHA functional classification is reduced from class II to class I.

52. The method of any one of claims **35** to **39**, wherein administration of a therapeutically effective amount of Compound 1 in a subject with ATTR cardiomyopathy improves, stabilizes or delays worsening in the Kansas City Cardiomyopathy Questionnaire (KCCQ) classification of subjects.

53. The method of claim **52**, wherein subjects have an average improvement of at least one level in the Kansas City Cardiomyopathy Questionnaire (KCCQ) classification of subjects.

54. The method of any one of claims **35** to **39**, wherein administration of a therapeutically effective amount of Compound 1 in a subject with ATTR cardiomyopathy improves, stabilizes or delays worsening in the EuroQoL-5 Dimensions (EQ-5D-5L) classification of subjects.

55. The method of claim **54**, wherein subjects have an average improvement of at least five points in the EuroQoL-5 Dimensions (EQ-5D-5L) utility score.

56. The method of any one of claims **35** to **39**, wherein administration of a therapeutically effective amount of Compound 1 in a subject with ATTR cardiomyopathy improves the subject's performance in a six minute walk test.

57. The method of claim **56**, wherein the subject walks at least 25 m further than a baseline distance measured prior to treatment with Compound 1.

58. The method of any one of claims **35** to **39**, wherein administration of a therapeutically effective amount of Compound 1 in a subject with ATTR cardiomyopathy decreases serum blood levels of brain natriuretic peptide (BNP).

59. The method of claim **58**, wherein serum blood levels of BNP of said subject decreases at least 10% as compared to a baseline level of BNP in said subject prior to treatment with Compound 1.

60. The method of any one of claims **35** to **39**, wherein administration of a therapeutically effective amount of Compound 1 in a subject with ATTR cardiomyopathy decreases serum blood levels of N-terminal pro-brain natriuretic peptide (N-terminal pro-BNP).

61. The method of claim **60**, wherein serum blood levels of N-terminal pro-BNP of said subject decreases at least 10% as compared to a baseline level of N-terminal pro-BNP in said subject prior to treatment with Compound 1.

62. The method of any one of claims **35** to **39**, wherein administration of a therapeutically effective amount of Compound 1 in a subject with ATTR cardiomyopathy decreases the frequency of cardiovascular-related hospitalizations as compared to subjects not receiving treatment.

63. The method of any one of claims **35** to **39**, wherein administration of a therapeutically effective amount of Compound 1 in a subject with ATTR cardiomyopathy decreases mortality as compared to subjects not receiving treatment.

64. The method of any one of claims **40** to **43**, wherein administration of a therapeutically effective amount of Compound 1 in a subject with ATTR polyneuropathy improves the Neuropathy Impairment Score (NIS) in said subject.

65. The method of claim **64**, wherein the NIS score is reduced by at least 10 % as compared to a baseline level measured prior to treatment with Compound 1.

66. The method of any one of claims **40** to **43**, wherein administration of a therapeutically effective amount of Compound 1 in a subject with ATTR polyneuropathy improves the modified Neuropathy Impairment Score+7 (mNIS+7) in said subject.

67. The method of claim **66**, wherein the mNIS+7 score is reduced by at least 10 % as compared to a baseline level measured prior to treatment with Compound 1.

68. The method of any one of claims **40** to **43**, wherein administration of a therapeutically effective amount of Compound 1 in a subject with ATTR polyneuropathy improves the subject's Norfolk Quality of Life Diabetic Neuropathy (QOL-DN) questionnaire score.

69. The method of claim **68**, wherein the Norfolk QOL-DN score is improved by at least 10 % as compared to a baseline level measured prior to treatment with Compound 1.

70. The method of any one of claims **40** to **43**, wherein administration of a therapeutically effective amount of Compound 1 in a subject with ATTR polyneuropathy improves the subject's composite autonomic symptom score (COMPASS-31) score.

71. The method of claim **70**, wherein the COMPASS-31 score is improved by at least 0.5 points as compared to a baseline level measured prior to treatment with Compound 1.

72. The method of any one of claims **40** to **43**, wherein administration of a therapeutically effective amount of Compound 1 in a subject with ATTR polyneuropathy improves the modified BMI (mBMI) of the subject.

73. The method of any one of claims **40** to **43**, wherein administration of a therapeutically effective amount of Compound 1 in a subject with ATTR polyneuropathy improves the 10-meter walk test speed of the subject.

74. The method of any one of claims **1** to **73**, wherein Compound 1 is administered chronically.

75. The method of any one of claims **1** to **73**, wherein Compound 1 is administered for 28 days.

76. The method of any one of claims **1** to **73**, wherein Compound 1 is administered for 56 days.

77. The method of any one of claims **1** to **73**, wherein Compound 1 is administered for 84 days.


78. The method of any one of claims **1** to **73**, wherein Compound 1 is administered for 18 months.

79. The method of any one of claims **1** to **73**, wherein Compound 1 is administered for 30 months.

80. The method of any one of claims **1** to **79**, wherein the subject is receiveing a diuretic therapy agent.

81. The method of claim **81**, wherein the diuretic therapy agent is furosemide or torsemide.

82. A single unit dosage comprising about 10-1,000 mg of Compound 1, having the formula:



, or a pharmaceutically acceptable salt thereof.

83. The single unit dosage form of claim **82**, wherein the single unit dosage form comprises about 200 mg of Compound 1.

84. The single unit dosage form of claim **82**, wherein the single unit dosage form comprises about 400 mg of Compound 1.

85. The single unit dosage of any one of claims **82** to **84**, wherein the single unit dosage form is a tablet.

86. The single unit dosage of any one of claims **82** to **84**, wherein the singe unit dosage form is a capsule.

87. The singe unit dosage of any one of claims **82** to **86**, wherein Compound 1 is in HCl salt form.

88. A kit comprising one or more unit dosages of any one of claims **82** to **87**.

89. The kit of claim **88**, further comprising a label with instructions for administering Compound 1.